Lakewood-Amedex Biotherapeutics, Inc.
LABTHealthcare|Biotechnology|US
$0.39
-0.15 (-28.54%)
Tangible Book / Share
$3.05
Cash / Share
$3.23
Financials
Financial Snapshot
Market Cap
$676.3K
Enterprise Value
-$1.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$7.3M
Cash & Investments
$4.6M
Net Cash
$4.5M
Free Cash Flow (TTM)
-$3.5M
Operating CF (TTM)
-$3.5M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$4.6M
Quarterly Burn
$871.4K
Monthly Burn
$290.5K
Est. Runway
~5.3 quarters
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Cash & Investments | — | — | $236.4K | $4.6M | |
| Operating Cash Flow | — | — | -$1.9M | -$3.5M | |
| Free Cash Flow | — | — | -$1.9M | -$3.5M | |
| Capital Expenditure | — | — | $0.00 | $0.00 | |
| Financing Cash Flow | — | — | $1.5M | $6.8M |
R&D Spending
R&D (TTM)
$1.6M
R&D Intensity
—
R&D Growth vs Prior
+29.4%
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $5.5M | $2.1M | $1.3M | $1.6M | |
| SG&A | $3.1M | $1.9M | $2.5M | $5.6M |
Income Statement
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $5.5M | $2.1M | $1.3M | $1.6M | |
| SG&A | $3.1M | $1.9M | $2.5M | $5.6M | |
| Operating Income | -$8.6M | -$4.0M | -$3.8M | -$7.3M | |
| Interest Expense | $10.0K | $5.0K | $100.9K | $124.5K | |
| Pretax Income | -$8.3M | -$4.9M | -$3.8M | -$7.3M | |
| Net Income | -$8.3M | -$4.9M | -$3.8M | -$7.3M | |
| EPS (Diluted) | -11.84 | -6.94 | -2.76 | -10.02 | |
| EBITDA | -$8.2M | -$4.7M | -$3.6M | -$7.1M | |
| Shares Out. (M) | 0.70 | 0.70 | 1.39 | 1.42 |
Balance Sheet
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $236.4K | $2.6M | |
| Short-Term Investments | — | — | $0.00 | $2.0M | |
| Total Current Assets | — | — | $305.4K | $4.8M | |
| Total Assets | — | — | $481.6K | $5.0M | |
| Total Current Liabilities | — | — | $2.4M | $628.9K | |
| Long-Term Debt | — | — | $0.00 | $0.00 | |
| Total Liabilities | — | — | $2.4M | $628.9K | |
| Stockholders' Equity | — | — | -$2.0M | $4.3M | |
| Retained Earnings | — | — | -$53.4M | -$68.6M |
Cash Flow Statement
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Operating Cash Flow | — | — | -$1.9M | -$3.5M | |
| Capital Expenditure | — | — | $0.00 | $0.00 | |
| Free Cash Flow | — | — | -$1.9M | -$3.5M | |
| Investing Cash Flow | — | — | $0.00 | -$2.0M | |
| Financing Cash Flow | — | — | $1.5M | $6.8M | |
| Issuance of Stock | — | — | $0.00 | $0.00 | |
| Repurchase of Stock | — | — | $0.00 | $0.00 | |
| Net Debt Issuance | — | — | $1.5M | $125.0K | |
| Stock Based Comp. | — | — | $1.4M | $1.4M | |
| Net Change in Cash | — | — | -$444.7K | $1.3M |
Dilution Tracker
Shares outstanding grew 99.2% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+99.2%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Shares Out. (M) | 0.70 | 0.70 | 1.39 | 1.42 | |
| Change vs Prior % | — | 0.0% | 99.2% | 1.9% | |
| Stock Issuance | — | — | $0.00 | $0.00 | |
| Stock Repurchase | — | — | $0.00 | $0.00 | |
| Stock Based Comp. | — | — | $1.4M | $1.4M |
Margins & Profitability
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| ROE % | 0.0% | 0.0% | 195.9% | 1687.7% | |
| ROA % | 0.0% | 0.0% | -798.9% | -148.1% | |
| ROIC % | 0.0% | 0.0% | 1240.1% | -164.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 53.4% | 6.3% | |
| Net Income | 0.0% | 41.4% | 20.8% | |
| EPS (Diluted) | 0.0% | 41.4% | 60.2% | |
| Operating Cash Flow | 0.0% | 0.0% | 0.0% | |
| Free Cash Flow | 0.0% | 0.0% | 0.0% | |
| R&D Expense | 0.0% | -62.0% | -40.3% | |
| SG&A Expense | 0.0% | -38.1% | 31.1% | |
| Total Assets | 0.0% | 0.0% | 0.0% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | |
| Debt | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 99.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.13
EV/EBITDA0.25
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$3.05
Net Current Assets / Share
$2.41
Graham Net-Net
$2.79
Cash / Share
$3.23
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| P/E Ratio | -7.31 | -12.46 | -31.34 | -0.04 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | 0.00 | -61.36 | 0.13 | |
| EV/EBITDA | 0.00 | 0.00 | -33.63 | 0.25 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | $6.9M | $223.0K | -$1.7M |
| EPS | $4.96 | $0.16 | $-1.23 |
| # Analysts (EPS) | 1 | 2 | 2 |